Research and Development Investment: AbbVie Inc. vs Celldex Therapeutics, Inc.

R&D Investment Trends: AbbVie vs Celldex (2014-2023)

__timestampAbbVie Inc.Celldex Therapeutics, Inc.
Wednesday, January 1, 20143297000000104381000
Thursday, January 1, 20154285000000100171000
Friday, January 1, 20164366000000102726000
Sunday, January 1, 2017498200000096171000
Monday, January 1, 20181032900000066449000
Tuesday, January 1, 2019640700000042672000
Wednesday, January 1, 2020655700000042534000
Friday, January 1, 2021708400000053311000
Saturday, January 1, 2022651000000082258000
Sunday, January 1, 20238453000000118011000
Monday, January 1, 202412791000000
Loading chart...

Unleashing insights

A Decade of R&D Investment: AbbVie Inc. vs Celldex Therapeutics, Inc.

In the competitive landscape of biotechnology, research and development (R&D) investments are crucial for innovation and growth. Over the past decade, AbbVie Inc. and Celldex Therapeutics, Inc. have demonstrated contrasting strategies in their R&D expenditures. From 2014 to 2023, AbbVie consistently increased its R&D spending, peaking in 2018 with a staggering 213% increase from 2014. This commitment underscores AbbVie's focus on expanding its pharmaceutical pipeline and maintaining its market leadership.

Conversely, Celldex Therapeutics, Inc. maintained a more conservative approach, with R&D expenses fluctuating modestly. Despite a 13% increase in 2023 compared to 2014, Celldex's R&D budget remains a fraction of AbbVie's. This disparity highlights the varied approaches companies take in the biotech sector, balancing risk and innovation. As the industry evolves, these investment strategies will continue to shape the future of healthcare innovation.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025